While caution is certainly warranted, we have paths to grow both full-year EBITDA and book value per share. Finally, we're seeing a modest shift toward to-be-built sales so far this year, which if ...
Thank you, Sally, and good morning, good afternoon, good evening to all of our shareholders, and welcome to all to ResMed's second quarter fiscal year 2026 earnings call. For this March and the June ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results